BAY 604552

Drug Profile

BAY 604552

Alternative Names: BAY-604552; BAY98-7081; sGC activator - Bayer

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Class Heart failure therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Erectile dysfunction; Heart failure

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 May 2011 Bayer completes a phase II trial in Erectile Dysfunction in Finland, France, Germany, Italy, Netherlands, Spain and Sweden (NCT01168817)
  • 24 Mar 2011 Bayer Healthcare completes enrolment in its phase II trial for Erectile dysfunction in Europe (NCT01168817)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top